A collaborative effort by cancer researchers at Cold Spring Harbor Laboratory (CSHL) and chemists at Boehringer Ingelheim (BI),a pharmaceutical firm, has resulted in the identification of a current drug target in leukemia and creation of a candidate drug that hits the target. Perhaps even more principal, or the research demonstrates a current,highly accurate way of proving how this and certain other classes of drugs work—extremely valuable information in the risky business of drug development. The research appears today in Nature Chemical Biology.
Source: phys.org